Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.51 |
| ▸ | ITGAV | P06756 | 19/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.44 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919632 | 0.92 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL7919635 | 0.85 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL7856513 | 0.79 | ITGB3 (0.45) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL7498375 | 0.77 | ITGB3 (0.71) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL7498381 | 0.77 | ITGB3 (0.71) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL7864274 | 0.77 | LMNA (0.43) | ITGB3ITGA2B | |
| SCHEMBL7864322 | 0.76 | AURKA (0.41) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL6798729 | 0.73 | ITGB3 (0.44) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL13109233 | 0.73 | ITGB3 (0.67) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL6776399 | 0.73 | ITGB3 (0.75) | ITGB3ITGAVITGB6ITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689787-B1 | POTENTIATING TUMOR RESPONSE | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| EP-1140177-A2 | USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140193-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140183-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-0889877-B1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | SEARLE & CO (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000038719-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038715-A2 | USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| US-6833373-B1 | N-(3-hydroxy-5-((1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl) -amino)-benzoyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine and tamoxifen; breast cancer | G.D. SEARLE & CO. | 2004-12-21 | — | — | US | disclosed |
| US-20040234624-A1 | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | MCKEARN JOHN P (US) | 2004-11-25 | — | — | US | disclosed |
| US-6689787-B1 | POTENTIATING TUMOR RESPONSE | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | disclosed |
| EP-1140183-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140193-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0889877-B1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | SEARLE & CO (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000038719-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234624-A1 | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | ITGA2, ITGB5, ITGB2 | ITGB3 9/4885ITGAV 11/4885ITGB6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.